53427-77-3

Upstream product

• 1003-68-5 5-methyl-2-pyridone 
• 5720-07-0 4-methoxyphenylboronic acid 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 1003-68-5 5-methyl-pyridin-2-ol 

Downstream Products

• 1347692-55-0 1-(4-methoxyphenyl)-5-((m-tolylamino)methyl)pyridin-2(1H)-one 
• 1347692-53-8 1-(4-methoxyphenyl)-5-((o-tolylamino)methyl)pyridin-2(1H)-one 
• 1347692-52-7 1-(4-methoxyphenyl)-5-((p-tolylamino)methyl)pyridin-2(1H)-one 
• 1347692-51-6 1-(4-methoxyphenyl)-5-((phenylamino)methyl)pyridin-2(1H)-one 
• 1347692-47-0 1-(4-methoxyphenyl)-5-((4-methoxyphenylamino)methyl)pyridin-2(1H)-one 
• 1347692-45-8 5-((4-acetylphenylamino)methyl)-1-(4-methoxyphenyl)pyridin-2(1H)-one 
• 1347692-44-7 5-((4-chlorophenylamino)methyl)-1-(4-methoxyphenyl)pyridin-2(1H)-one 
• 1347692-71-0 C₁₃H₁₂BrNO₂ 
• 851518-71-3 1-(4-hydroxyphenyl)-5-methylpyridine-2(1H)-one 

Relevant academic research and scientific papers

Synthesis and anti-fibrotic effects of santamarin derivatives as cytotoxic agents against hepatic stellate cell line LX2

Liver fibrosis is a final result of extensive deposition of extracellular matrix (ECM) and starts with the activation and proliferation of hepatic stellate cells (HSCs). Our previous study showed that eudesmane sesquiterpenoid santamarin had cytotoxicity

Preparation method for hydronidone

The invention provides a preparation method for hydronidone. The preparation method has the advantages of simple and convenient operation, mild reaction conditions, short reaction time, high yield, more safety, and applicability to mass production. The pr

Pirfenidone structural isosteres: Design, synthesis and spectral study

Series of 5-substituted arylpyridin-2(1 H )-ones and arylpyrimidin-4(3 H )-ones were designed and synthesized based on pirfenidone, a compound which shows promising therapeutic effects for treatment of fibrosis. The compounds 1a - c , 2a - c and 3a - c were obtained under mild conditions by arylation of the appropriate heterocyclic amines with arylboronic acids under Chan-Lam- Evans conditions. The synthesis of the useful synthon N -(4-methoxyphenyl)-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan- 2-yl)-(1 H )-pyridin-2-one ( 4 ) is also reported. All compounds were characterized by spectral and elemental analysis and structural elucidation by 1 H and 13 C NMR is discussed herein.

COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.

THE DERIVATIVES OF PYRIDONE AND THE USE OF THEM

The present invention provides N-substituted-2(1H) pyridones or the pharmaceutical acceptable salts thereof, and the pharmaceutical preparations containing the compounds. The compounds of the present invention can be used to treat various fibrotic diseases effectively, e.g., hepatic fibrosis.

Compositions and methods for treatment of epilepsy

A method of treating a mammal with an epileptic condition, comprising: administering to said mammal a pharmaceutical composition containing an effective amount of an N-phenyl substituted 2-pyridone compound and/or pharmaceutically acceptable salts thereof.

TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS

In a preferred embodiment, a method of treating bacteria, fungi, and/or viruses on the surface of, or within, the layers of the dermis of skin, ears, fingernails, toenails, or hoofs of mammalian species, comprising: applying to the surface or layers a pharmaceutical substance including an effective amount of one or more 2-(1H) pyridone compound(s).

Treatment of cytokine growth factor caused disorders

In preferred embodiments, a method of prevention and treatment of disorders caused by enhanced proliferation and enhanced biosynthesis caused by cytokine growth factors in humans and other animals, the method including: administering to a human or other animal an effective dose of a pharmaceutical substance including an N-substituted 2(1H) pyridone and/or an N-substituted 3(1H) pyridone; and a composition for prevention and treatment of disorders caused by enhanced proliferation and enhanced biosynthesis caused by cytokine growth factors in humans and other animals, the composition including: a pharmaceutical preparation including an effective dose of an N-substituted 2(1H) pyridone and/or an N-substituted 3(1H) pyridone.

Compositions and method for treatment of lymphomas, leukemias, and leiomyomas

In a preferred embodiment, drugs having chemotherapeutic properties which are useful against certain neoplastic disorders with wide safety margins as evidenced by their low toxicity, and molecular actions. Such drugs include as active ingredient(s) one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridone(s). The compositions of this invention are novel as anti-neoplastic drugs, namely as an agent for treating leukemias, lymphomas, and leiomyomas.

Inhibition of tumor necrosis factor α

In a preferred embodiment, a method for the inhibition of the synthesis and release of tumor necrosis factor from various cells, comprising: administering to a human or other mammal an effective dose of one or more pharmaceutical substances selected from the group consisting of N-substituted 2(1H)pyridones, N-substituted 3(1H)pyridones, and pharmaceutically acceptable salts thereof.